Aim: Adriamycin (ADR) is an antineoplastic drug that
is widely used in chemotherapy but its cardiotoxicity is the most important
side effect that limits the clinical use of this drug. In this study, we
investigated of edaravone (EDO), which is a potent antioxidant, ADR-induced
cardiotoxicity model in rats by electrocardiographic (ECG), biochemical and
scintigraphic methods.
Methods: Twenty-eight adult male
Wistar-Albino rats were randomly separated into four groups; namely control
(CON); Adriamycin (ADR); substance control of edaravone (EDO), edaravone +
adriamycin (EDO+ADR) groups. Cardiotoxicity in rats was induced by adriamycin
injection (cumulative dose:18 mg/kg, intraperitoneal-i.p.-) at an interval of
24 hours (h) on the 5th, 6th and 7th days.
Rats receiving edaravone treatment in the adriamycin group administration
edaravone (30 mg/kg/day, i.p.) for 7 days and were injected with adriamycin (18
mg/kg, i.p.) on 5th, 6th and 7th days.
On the 8th day electrocardiography (ECG), biochemical and
technetium-99m pyrophosphate (99mTc-PYP) scintigraphic parameters
were assessed.
Results: ADR
induction caused changes in the ECG pattern, decreased heartbeat, P wave and
QRS complex duration, increased both ST-segment amplitude and QT interval
duration (p < 0,001), increase in the biochemical markers [blood urea
nitrogen (BUN), creatine kinase (CK), cardiac troponin T (cTnT)], and
elevated 99mTc-PYP uptake level (p < 0,001). EDO
treatment prevented all the parameters of ADR-induced cardiotoxicity in rats,
by significantly decreased all ADR-associated conduction abnormalities in
ECG (p < 0.001), decreased 99mTc-PYP uptake (p <
0.001) and serum BUN, CK and cTnT, (p < 0.001).
Conclusions: Our data demonstrate
that EDO has cardioprotective effects on DOX-induced cardiotoxicity. At the
same time, this study suggested that 99mTc-PYP may be using as
a non-invasive method for the early diagnosis of ADR-induced cardiotoxicity.
Birincil Dil | İngilizce |
---|---|
Konular | Sağlık Kurumları Yönetimi |
Bölüm | Temel Tıp Bilimleri Araştırma Yazıları |
Yazarlar | |
Yayımlanma Tarihi | 28 Mart 2019 |
Kabul Tarihi | 25 Mart 2019 |
Yayımlandığı Sayı | Yıl 2019Cilt: 41 Sayı: 1 |